All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Menin inhibition in relapsed/refractory AML: what do the data tell us?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub was pleased to speak to Ghayas Issa, MD Anderson Cancer Centre, Houston, US. We asked, What do the data tell us about menin inhibition in relapsed/refractory acute myeloid leukemia (AML)?

Menin inhibition in relapsed/refractory AML: what do the data tell us?

Issa explains the mechanism of action of menin inhibitors, then goes on to describe the positive findings from phase I studies of ziftomenib and revumenib in relapsed/refractory AML, including for patients with NPM1 mutations and KMT2A rearrangements. Issa also discusses data for a subset of patients treated with revumenib who underwent hematopoietic stem cell transplantation and outlines plans for combination studies of menin inhibitors with other agents.